Therese M Becker

List of Publications by Year
in descending order

63 papers	2,064 citations	257101 24 h-index	253896 43 g-index
64 all docs	64 docs citations	64 times ranked	3803 citing authors

#	Article	IF	Citations
1	Optimising alkalinisation and its effect on QRS narrowing in tricyclic antidepressant poisoning. British Journal of Clinical Pharmacology, 2022, 88, 723-733.	1.1	2
2	Biomarkers of Castrate Resistance in Prostate Cancer: Androgen Receptor Amplification and T877A Mutation Detection by Multiplex Droplet Digital PCR. Journal of Clinical Medicine, 2022, 11, 257.	1.0	6
3	Prognostic and Predictive Value of Liquid Biopsy-Derived Androgen Receptor Variant 7 (AR-V7) in Prostate Cancer: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2022, 12, 868031.	1.3	7
4	Harnessing Liquid Biopsies to Guide Immune Checkpoint Inhibitor Therapy. Cancers, 2022, 14, 1669.	1.7	6
5	Circulating tumour cells in pancreatic cancer: A systematic review and meta-analysis of clinicopathological implications. Pancreatology, 2021, 21, 103-114.	0.5	11
6	The Multiple Potential Biomarkers for Predicting Immunotherapy Response—Finding the Needle in the Haystack. Cancers, 2021, 13, 277.	1.7	16
7	PD-L1 Detection on Circulating Melanoma Cells. Methods in Molecular Biology, 2021, 2265, 223-233.	0.4	1
8	Human TERT promoter mutations as a prognostic biomarker in glioma. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1007-1017.	1.2	21
9	Tumour immune microenvironment biomarkers predicting cytotoxic chemotherapy efficacy in colorectal cancer. Journal of Clinical Pathology, 2021, 74, 625-634.	1.0	18
10	Association between shift work and cognitive performance on the Trail Making Test in emergency department health officers. EMA - Emergency Medicine Australasia, 2021, 33, 711-717.	0.5	6
11	Plasma pre-treatment T790M relative allelic frequency in patients with advanced EGFR-mutated non-small cell lung cancer predicts treatment response to subsequent-line osimertinib. Translational Lung Cancer Research, 2021, 10, 1623-1634.	1.3	5
12	HGF/c-Met Inhibition as Adjuvant Therapy Improves Outcomes in an Orthotopic Mouse Model of Pancreatic Cancer. Cancers, 2021, 13, 2763.	1.7	7
13	Combination chemotherapy with NAB ® €paclitaxel and capecitabine for patients with advanced biliary tract cancer (NAP€CAPABIL Pilot Study). Asia-Pacific Journal of Clinical Oncology, 2021, , .	0.7	5
14	Comparison of neutrophil to lymphocyte ratio and prognostic nutritional index with other clinical and molecular biomarkers for prediction of glioblastoma multiforme outcome. PLoS ONE, 2021, 16, e0252614.	1.1	8
15	Experimental and Clinical Evidence Supports the Use of Urokinase Plasminogen Activation System Components as Clinically Relevant Biomarkers in Gastroesophageal Adenocarcinoma. Cancers, 2021, 13, 4097.	1.7	6
16	The Role of Liquid Biopsies in Detecting Molecular Tumor Biomarkers in Brain Cancer Patients. Cancers, 2020, 12, 1831.	1.7	29
17	Endocrine Resistance in Breast Cancer: The Role of Estrogen Receptor Stability. Cells, 2020, 9, 2077.	1.8	17
18	Isolation of Circulating Tumor Cells from Glioblastoma Patients by Direct Immunomagnetic Targeting. Applied Sciences (Switzerland), 2020, 10, 3338.	1.3	11

#	Article	IF	Citations
19	Establishment of novel long-term cultures from EpCAM positive and negative circulating tumour cells from patients with metastatic gastroesophageal cancer. Scientific Reports, 2020, 10, 539.	1.6	30
20	The Prospect of Identifying Resistance Mechanisms for Castrate-Resistant Prostate Cancer Using Circulating Tumor Cells: Is Epithelial-to-Mesenchymal Transition a Key Player?. Prostate Cancer, 2020, 2020, 1-16.	0.4	10
21	An Orthotopic Resectional Mouse Model of Pancreatic Cancer. Journal of Visualized Experiments, 2020, , .	0.2	3
22	Plasma next generation sequencing and droplet digital PCRâ€based detection of epidermal growth factor receptor (EGFR) mutations in patients with advanced lung cancer treated with subsequentâ€line osimertinib. Thoracic Cancer, 2019, 10, 1879-1884.	0.8	36
23	Detection of AR-V7 in Liquid Biopsies of Castrate Resistant Prostate Cancer Patients: A Comparison of AR-V7 Analysis in Circulating Tumor Cells, Circulating Tumor RNA and Exosomes. Cells, 2019, 8, 688.	1.8	40
24	Expression of cancer stem cell markers is prognostic in metastatic gastroesophageal adenocarcinoma. Pathology, 2019, 51, 474-480.	0.3	11
25	Immunomagnetic isolation of circulating melanoma cells and detection of PD-L1 status. PLoS ONE, 2019, 14, e0211866.	1.1	16
26	Droplet Digital PCR Based Detection of EGFR Mutations in Advanced Lung Cancer Patient Liquid Biopsies: A Comparison of Circulating Tumour DNA Extraction Kits. Journal of Molecular Biomarkers & Diagnosis, 2018, 09, .	0.4	3
27	Improved ovarian cancer EMT-CTC isolation by immunomagnetic targeting of epithelial EpCAM and mesenchymal N-cadherin. Journal of Circulating Biomarkers, 2018, 7, 184945441878261.	0.8	47
28	Cryopreservation for delayed circulating tumor cell isolation is a valid strategy for prognostic association of circulating tumor cells in gastroesophageal cancer. World Journal of Gastroenterology, 2018, 24, 810-818.	1.4	16
29	Circulating pancreatic stellate (stromal) cells in pancreatic cancerâ€"a fertile area for novel research. Carcinogenesis, 2017, 38, 588-591.	1.3	19
30	Clinical outcomes in patients with advanced epidermal growth factorâ€mutated nonâ€smallâ€cell lung cancer in South Western Sydney Local Health District. Internal Medicine Journal, 2017, 47, 1405-1411.	0.5	14
31	CTC-mRNA (AR-V7) Analysis from Blood Samplesâ€"Impact of Blood Collection Tube and Storage Time. International Journal of Molecular Sciences, 2017, 18, 1047.	1.8	21
32	The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis. Oncotarget, 2017, 8, 23099-23109.	0.8	46
33	Droplet Digital PCR Based Androgen Receptor Variant 7 (AR-V7) Detection from Prostate Cancer Patient Blood Biopsies. International Journal of Molecular Sciences, 2016, 17, 1264.	1.8	50
34	Gastric cancer stem cells: evidence, potential markers, and clinical implications. Journal of Gastroenterology, 2016, 51, 313-326.	2.3	109
35	Predictive and prognostic value of circulating tumor cell detection in lung cancer: A clinician's perspective. Critical Reviews in Oncology/Hematology, 2015, 93, 90-102.	2.0	33
36	New frontiers in circulating tumor cell analysis: A reference guide for biomolecular profiling toward translational clinical use. International Journal of Cancer, 2014, 134, 2523-2533.	2.3	31

#	Article	IF	Citations
37	BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact. Clinical Cancer Research, 2014, 20, 1965-1977.	3.2	447
38	Secondary c‑Kit mutations confer acquired resistance to RTK inhibitors in c‑Kit mutant melanoma cells. Pigment Cell and Melanoma Research, 2013, 26, 518-526.	1.5	31
39	Vemurafenib Induces Senescence Features in Melanoma Cells. Journal of Investigative Dermatology, 2013, 133, 1601-1609.	0.3	95
40	Oncogenic B-RAFV600E Signaling Induces the T-Box3 Transcriptional Repressor to Repress E-Cadherin and Enhance Melanoma Cell Invasion. Journal of Investigative Dermatology, 2013, 133, 1269-1277.	0.3	44
41	Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma. Molecular Cancer Therapeutics, 2013, 12, 1332-1342.	1.9	71
42	Molecular Mechanisms of Cellular Senescence. , 2013, , .		5
43	Acquired Resistance to BRAF Inhibition Can Confer Cross-Resistance to Combined BRAF/MEK Inhibition. Journal of Investigative Dermatology, 2012, 132, 1850-1859.	0.3	76
44	Absence of Distinguishing Senescence Traits in Human Melanocytic Nevi. Journal of Investigative Dermatology, 2012, 132, 2226-2234.	0.3	50
45	Selective Loss of Wild-Type p16INK4a Expression in Human Nevi. Journal of Investigative Dermatology, 2011, 131, 2329-2332.	0.3	9
46	Predicting functional significance of cancer-associated p16INK4a mutations in CDKN2A. Human Mutation, 2010, 31, 692-701.	1.1	37
47	Oncogenic B-RAFV600E Promotes Anchorage-Independent Survival of Human Melanocytes. Journal of Investigative Dermatology, 2010, 130, 2144-2147.	0.3	11
48	Amino terminal hydrophobic import signals target the p14ARF tumor suppressor to the mitochondria. Cell Cycle, 2010, 9, 829-839.	1.3	26
49	IGFBP7 Is Not Required for B-RAF-Induced Melanocyte Senescence. Cell, 2010, 141, 717-727.	13.5	60
50	Oncogene-Induced Senescence Does Not Require the p16INK4a or p14ARF Melanoma Tumor Suppressors. Journal of Investigative Dermatology, 2009, 129, 1983-1991.	0.3	68
51	The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4a. Molecular Cancer, 2009, 8, 4.	7.9	55
52	Wild type and melanoma‑associated mutant p16INK4a proteins do not oligomerize in vivo. Pigment Cell and Melanoma Research, 2009, 22, 131-133.	1.5	3
53	The relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence. Aging, 2009, 1, 542-556.	1.4	70
54	p16INK4a‑induced senescence is disabled by melanoma‑associated mutations. Aging Cell, 2008, 7, 733-745.	3.0	59

#	Article	IF	Citations
55	Physical and Functional Interaction of the p14ARF Tumor Suppressor with Ribosomes. Journal of Biological Chemistry, 2006, 281, 38080-38088.	1.6	19
56	The melanoma-associated 24 base pair duplication in p16INK4a is functionally impaired. International Journal of Cancer, 2005, 117, 569-573.	2.3	6
57	eMelanoBase: An online locus-specific variant database for familial melanoma. Human Mutation, 2003, 21, 2-7.	1.1	15
58	Association of p14ARF with the p120E4FTranscriptional Repressor Enhances Cell Cycle Inhibition. Journal of Biological Chemistry, 2003, 278, 4981-4989.	1.6	47
59	Regulation of Cellular Senescence by the Retinoblastoma Pathway. , 2003, , 151-169.		1
60	Cell cycle regulation in the melanocyte. , 2003, , 13-24.		2
61	Differential expression of p16INK4a and p16Î² transcripts in B-lymphoblastoid cells from members of hereditary melanoma families without CDKN2A exon mutations. Oncogene, 1997, 15, 515-523.	2.6	24
62	Importance and Detection of Epithelial-to-Mesenchymal Transition (EMT) Phenotype in CTCs. , 0, , .		0
63	Prognostic and Predictive Value of CCND1/Cyclin D1 Amplification in Breast Cancer With a Focus on Postmenopausal Patients: A Systematic Review and Meta-Analysis. Frontiers in Endocrinology, 0, 13, .	1.5	14